Protocol 2: Intermediate approach (experienced researchers) Goal: Multi-target immune modulation with anti-inflammatory support Components: Thymosin alpha-1: 1.6 mg subcutaneously, three times weekly KPV: 200-500 mcg subcutaneously, once daily BPC-157: 250 mcg subcutaneously, twice daily Selank: 250-500 mcg intranasally, once daily Schedule: Monday, Wednesday, Friday: Thymosin alpha-1 Daily AM: KPV + BPC-157 Daily PM: BPC-157 Daily: Selank nasal spray (morning or midday) Duration: 12 weeks on, 4 weeks off Monitoring: Baseline labs, repeat every 4 weeks
A licensed healthcare provider will review your medical questionnaire and prescribe treatment only if medically appropriate
No head-to-head trial has compared the two, so every direct comparison here is cross-trial inference
Mol Cell Biochem 293:211219 Kamel MY, Ahmed SM, Abdelzaher WY, Welson NN, Abdel-Aziz AM (2022) Role of IL-6/STAT3 pathway in mediating the protective effect of agomelatine against methotrexate-induced lung/intestinal tissues damage in rats
Booking is simple